Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen

BMC Biotechnology

Volumn 15, Issue 1, 2015, Pages

  Pleckaityte, Milda ^a   Bremer, Corinna M ^b   Gedvilaite, Alma ^a   Kucinskaite Kodze, Indre ^a   Glebe, Dieter ^b   Zvirbliene, Aurelija ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; EPITOPES; MOLECULES; MONOCLONAL ANTIBODIES; PROTEINS; PURIFICATION; SELF ASSEMBLY; VIRUSES; YEAST;

ANTIGEN-BINDING ACTIVITIES; DENSITY GRADIENT CENTRIFUGATION; HEPATITIS B VIRUS SURFACE ANTIGENS; HETEROLOGOUS EXPRESSION; NEUTRALIZING ANTIBODIES; REPETITIVE STRUCTURE; THERAPEUTIC TREATMENTS; YEAST SACCHAROMYCES CEREVISIAE;

ANTIBODIES;

HEPATITIS B SURFACE ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN VP1; PROTEIN VP2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; IN VITRO STUDY; LIVER CELL; MOLECULAR SIZE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYOMAVIRUS; PROTEIN ASSEMBLY; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; SACCHAROMYCES CEREVISIAE; SCANDENTIA; TUPAIA BELANGERI; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; GENETICS; IMMUNOLOGY; TUPAIA; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATOCYTES; POLYOMAVIRUS; SACCHAROMYCES CEREVISIAE; TUPAIA; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84941554039     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-015-0203-3     Document Type: Article

References (37)

1. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982;298:347-50.
2. Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, et al. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology. 1995;209:506-18.
3. Pumpens P, Grens E. Artificial genes for chimeric virus-like particles. In: Khudyakov YE, Fields HA, editors. Artificial DNA: methods and applications. Boca Raton: CRC Press LLC; 2002. p. 249-327.
4. Zeltins A. Construction and characterization of virus-like particles. Mol Biotechnol. 2013;53:92-107.
5. Pushko P, Pumpens P, Grens E. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology. 2013;56:141-65.
6. Sasnauskas K, Buzaite O, Vogel F, Jandrig B, Razanskas R, Staniulis J, et al. Yeast cells allow the high-level expression and formation of polyomavirus-like particles. Biol Chem. 1999;380:381-6.
7. Griffith JP, Griffith DL, Rayment I, Murakami WT, Caspar DL. Inside polyomavirus at 25-Å resolution. Nature. 1992;355:652-4.
8. Gedvilaite A, Frommel C, Sasnauskas K, Burkhard M, Ozel M, Behrsing O, et al. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster major capsid protein. Virology. 2000;273:21-35.
9. Gedvilaite A, Zvirbliene A, Staniulis J, Sasnauskas K, Krüger DH, Ulrich R. Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice. Viral Immunol. 2004;17:51-68.
10. Zvirbliene A, Samonskyte L, Gedvilaite A, Voronkova T, Ulrich R, Sasnauskas K. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles. J Immunol Methods. 2006;311:57-70.
11. Dorn DC, Lawatscheck R, Zvirbliene A, Aleksaite E, Pecher G, Sasnauskas K, et al. Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope. Viral Immunol. 2008;21:12-27.
12. Pleckaityte M, Zvirbliene A, Sezaite I, Gedvilaite A. Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin. Microb Cell Fact. 2011;10:109.
13. Liddington RC, Yan Y, Moulai J, Sahli R, Benjamin TL, Harrison SC. Structure of simian virus 40 at 3.8Å resolution. Nature. 1991;354:278-84.
14. Stehle T, Yan Y, Benjamin TL, Harrison SC. Structure of murine polyomavirus complexed with an oligosaccharide receptor fragment. Nature. 1994;369:160-3.
15. Tegerstedt K, Franzen A, Ramqvist T, Dalianis T. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol Immunother. 2007;56:1335-44.
16. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni GT, et al. A single vaccination with polyomavirus VP1/ VP2 Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res. 2005;65:5953-7.
17. Eriksson M, Andreasson K, Weidmann J, Lundberg K, Tegerstedt K, Dalianis T, et al. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS One. 2011;6, e23828.
18. Fric J, Marek M, Hruskova V, Holan V, Forstova J. Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration. Vaccine. 2008;26:3242-51.
19. Lasickiene R, Gedvilaite A, Norkiene M, Simanaviciene V, Sezaite I, Dekaminaviciute D, et al. The use of recombinant pseudotype virus-like particles harbouring inserted target antigen to generate antibodies against cellular marker p16INK4A. ScientificWorldJournal. 2012;2012:263737.
20. Pleckaityte M, Mistiniene E, Lasickiene R, Zvirblis G, Zvirbliene A. Generation of recombinant single-chain antibodies neutralizing the cytolytic activity of vaginolysin, the main virulence factor of Gardnerella vaginalis. BMC Biotechnol. 2011;11:100.
21. Moutel S, El Marjou A, Vielemeyer O, Nizak C, Benaroch P, Dübel S. A multi-Fc-species system for recombinant antibody production. BMC Biotechnol. 2009;9:14.
22. Benhar I, Pastan I. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. J Biol Chem. 1995;270:23373-80.
23. Seo MJ, Jeong KJ, Leysath CE, Ellington AD, Iverson BL, Georgiou G. Engineering antibody fragments to fold in the absence of disulfide bonds. Protein Sci. 2009;18:259-67.
24. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD. Engineered human antibody constant domains with increased stability. J Biol Chem. 2009;284:14203-10.
25. Glebe D, Urban S, Knoop E, Çağ N, Krass P, Grün S, et al. Mapping of hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and Tupaia hepatocytes. Gastroenterology. 2005;129:234-45.
26. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A. 2012;109:5034-9.
27. Scott LJ, Lamb HM. Palivizumab. Drugs. 1999;5:305-11.
28. Kouiavskaia D, Chen Z, Dragunsky E, Mirochnitchenko O, Purcell R, Chumakov K. A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses. J Clin Virol. 2015;65:32-7.
29. Clementi N, Criscuolo E, Castelli M, Clementi M. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. New Microbiol. 2012;35:399-406.
30. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. Passive immunity in the prevention of rabies. Lancet Infect Dis. 2012;12:397-407.
31. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346-58.
32. Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A. 2011;108:16998-7003.
33. Bremer CM, Sominskaya I, Skrastina D, Pumpens P, Abd El Wahed A, Beutling U, et al. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol. 2011;55:29-37.
34. Cerino A, Bremer CM, Glebe D, Mondelli MU. A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity. PLoS One. 2015;10, e0125704.
35. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 4th ed. Cold Spring Harbour: Cold Spring Harbor Press; 2001.
36. Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, et al. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease. J Immunol Methods. 2000;13:167-77.
37. Bradford MM. A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.